Colorectal cancer is becoming increasingly common among people under the age of fifty. But why do younger patients often have poorer outcomes? Could the disease behave differently in this age group, or even be more aggressive?
To investigate, CCA principal investigator and medical oncologist Tineke Buffart and her colleagues analysed data from more than 80,000 colorectal cancer patients across the Netherlands, diagnosed between 2016 and 2022. Their findings, published last week in eClinicalMedicine, offer important new insights. The study was also featured in Clinical Research in Oncology's list of 'Recent high impact studies in clinical oncology'.
Younger patients more likely to die
The researchers divided patients into three age groups:
Younger patients (under 50)
Middle-aged patients (50–69)
Older patients (70 and above)
The results showed that younger patients are indeed more likely to die from colorectal cancer than those aged 50 to 69. However, when the researchers compared patients with similar disease characteristics who received the same treatment, the difference in survival almost completely disappeared.
Not more aggresive
This suggests that colorectal cancer is not inherently more aggressive in younger patients. Instead, the main issue is that the disease is often diagnosed at a more advanced stage. There are several possible explanations for this. People under fifty are not included in the national colorectal cancer screening programme, and when symptoms do occur, cancer may not immediately be suspected. This can lead to delays in diagnosis, giving the disease more time to progress.
More intensive treatment is not always better
Another important finding was that younger patients were considerably more likely to receive intensive treatment, such as chemotherapy involving three drugs rather than two, even though this did not always lead to better outcomes. The researchers therefore caution against overtreatment: younger age does not automatically justify more aggressive therapy. More intensive treatment can cause additional side effects and negatively affect quality of life.
"Being young is not, in itself, a reason to intensify treatment," Buffart emphasises. "Treatment decisions should be based on the characteristics of the tumour and the patient's overall condition, rather than age alone."
What does this mean for patients and society?
The findings suggest that earlier detection could play an important role in improving survival among younger colorectal cancer patients. However, achieving this is not straightforward. Colorectal cancer often causes few or no symptoms in its early stages, making it difficult to recognise. In addition, people under fifty are not covered by the national screening programme.
"It is important to remain aware that colorectal cancer can also occur in younger people," Buffart stresses.
Detecting the disease at an earlier stage can increase the chances of successful treatment and may reduce the need for intensive therapy.